Parametric Portfolio Associates LLC Has $35.30 Million Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Share on StockTwits

Parametric Portfolio Associates LLC lowered its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 555,823 shares of the company’s stock after selling 7,595 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.38% of Henry Schein worth $35,295,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of HSIC. Longview Partners Guernsey LTD lifted its stake in Henry Schein by 15.8% in the second quarter. Longview Partners Guernsey LTD now owns 15,527,241 shares of the company’s stock valued at $1,085,354,000 after buying an additional 2,117,869 shares during the period. Pictet Asset Management Ltd. grew its position in shares of Henry Schein by 200.1% during the 3rd quarter. Pictet Asset Management Ltd. now owns 448,914 shares of the company’s stock worth $28,506,000 after buying an additional 897,302 shares during the period. APG Asset Management N.V. grew its position in shares of Henry Schein by 1,735.2% during the 2nd quarter. APG Asset Management N.V. now owns 822,308 shares of the company’s stock worth $50,474,000 after buying an additional 777,500 shares during the period. AQR Capital Management LLC increased its stake in shares of Henry Schein by 142.5% in the 2nd quarter. AQR Capital Management LLC now owns 927,381 shares of the company’s stock valued at $64,648,000 after acquiring an additional 544,893 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Henry Schein by 10,631.1% in the 2nd quarter. Nuveen Asset Management LLC now owns 462,295 shares of the company’s stock valued at $32,315,000 after acquiring an additional 457,987 shares in the last quarter.

In other news, CEO Stanley M. Bergman sold 90,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $67.51, for a total value of $6,075,900.00. Following the completion of the sale, the chief executive officer now directly owns 344,554 shares of the company’s stock, valued at $23,260,840.54. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Steven Paladino sold 21,370 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $68.83, for a total value of $1,470,897.10. Following the completion of the sale, the chief financial officer now directly owns 144,863 shares of the company’s stock, valued at $9,970,920.29. The disclosure for this sale can be found here. Insiders have sold 123,655 shares of company stock valued at $8,373,585 over the last quarter. Corporate insiders own 1.06% of the company’s stock.

Several research analysts recently issued reports on HSIC shares. BidaskClub raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Wednesday, November 27th. Piper Jaffray Companies raised their price target on shares of Henry Schein from $72.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. William Blair downgraded shares of Henry Schein from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 7th. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b” rating in a report on Monday, October 14th. Finally, ValuEngine raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Tuesday. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $72.17.

Shares of HSIC opened at $69.08 on Tuesday. The business’s fifty day moving average is $66.15 and its 200 day moving average is $65.81. Henry Schein, Inc. has a 12-month low of $56.58 and a 12-month high of $72.81. The company has a quick ratio of 0.92, a current ratio of 1.63 and a debt-to-equity ratio of 0.30. The stock has a market cap of $10.11 billion, a P/E ratio of 18.83, a P/E/G ratio of 2.71 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.90 EPS for the quarter, beating the Zacks’ consensus estimate of $0.86 by $0.04. Henry Schein had a net margin of 4.66% and a return on equity of 15.93%. The business had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.52 billion. During the same quarter in the previous year, the business posted $1.03 EPS. Henry Schein’s quarterly revenue was up 6.5% on a year-over-year basis. On average, analysts expect that Henry Schein, Inc. will post 3.45 EPS for the current year.

Henry Schein announced that its Board of Directors has initiated a stock buyback program on Thursday, October 31st that authorizes the company to buyback $400.00 million in shares. This buyback authorization authorizes the company to reacquire up to 4.3% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

See Also: How Do Tariffs Affect Trade Balances?

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.